Laurids Østergaard Poulsen

Laurids Østergaard Poulsen

Auto-generated profile, based on publicly available information

Laurids Østergaard Poulsen

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
LRLouise S. Rasmussen
Louise S. Rasmussen
MYMette K. Yilmaz
Mette K. Yilmaz
UFUrsula G. Falkmer
Ursula G. Falkmer
LPLaurids Ø. Poulsen
Laurids Ø. Poulsen
MBMartin Bøgsted
Martin Bøgsted
JJJulia Sidenius Johansen
Julia Sidenius Johansen

20 June 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Ismail GögenurIsmail Gögenur
Ismail Gögenur
TJTobias Freyberg Justesen
Tobias Freyberg Justesen
LTLine Schmidt Tarpgaard
Line Schmidt Tarpgaard
MBMustafa Bulut
Mustafa Bulut
THTorben Hansen
Torben Hansen
CQCamilla Qvortrup
Camilla Qvortrup
PURPOSE: Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and methods for response evaluation remain undefined. This trial aimed to investigate the efficacy and safety of neoadjuvant pembrolizumab for patients with localized dMMR colon cancer. METHODS: Participants received a single cycle of pembrolizumab (4 mg/kg, max 400 mg, every-6-weeks dosing regimen), followed by a preoperative endoscopy with biopsies and surgery 3-5 weeks later. The primary end point was pathologic complete response (pCR); secondary and exploratory end points included major pathologic response (MPR), safety, survival, and endoscopic response assessment. RESULTS: From February 2023 to March 2024, 85 patients (median age 74 years) were enrolled. All received pembrolizumab; one patient declined surgery. Among 84 patients, pCR was achieved in 44% (37 of 84; 95% CI, 33 to 55), and MPR in 57% (48 of 84; 95% CI, 46 to 68). Two (2%) patients died of complications within 30 days of surgery. At a median follow-up of 18.4 months (IQR, 16.3-21.1), one patient had a recurrence, resulting in overall and disease-free survival rates of 98% and 96%. Grade 3 adverse events occurred in 11% of patients (9 of 85; 95% CI, 3 to 16), with three treatment-related events. In 81 patients, the sensitivity, specificity, and accuracy of the biopsies for predicting pCR were 68%, 75%, and 72%, respectively. In 76 patients, the sensitivity, specificity, and accuracy of the endoscopic images for predicting pCR were 77%, 93%, and 86%, respectively. CONCLUSION: A single cycle of neoadjuvant pembrolizumab led to pCR in nearly half of patients undergoing surgery for localized dMMR colon cancer. The utility of endoscopic evaluation may inform future strategies for patient selection in nonoperative management pathways.

7 April 2022 in Clinical Oncology
Verified
Journal Article
Open access
CVC. Vesteghem
C. Vesteghem
RBR.F. Brøndum
R.F. Brøndum
MMMette Thune Mouritzen
Mette Thune Mouritzen
HCH.S. Christensen
H.S. Christensen
MBM. Bøgsted
M. Bøgsted
LPL.ø. Poulsen
L.ø. Poulsen
Risk factors for systemic anticancer therapies (SACTs) administered close to death derived from existing quality indicators are not directly applicable in the clinic, because they condition on future events, which leads to selection bias. This study aimed to adapt a previously suggested indicator for its use in a clinical context and to evaluate it in a real-world, population-based cohort of cancer patients. An improved version of the '30-day mortality after SACT' indicator suggested by Wallington et al. (Lancet Oncol 2016; 17:1203-16) was defined. All SACTs (n = 16 622) for all patients (n = 10 213) treated for common malignancies between 2009 and 2019 in the North Denmark Region were included. The results for the improved and Wallington's indicators were calculated and compared. Overall, the association between clinical variables and 30-day mortality following SACT was similar for both indicators, except for the 75+ years age group. However, Wallington's indicator showed varying absolute risk when comparing values for quarterly and yearly observation intervals. The improved and Wallington's indicators showed large differences between curative (1.0% and 1.1%, respectively) and palliative SACTs (9.1% and 11.7%, respectively). For palliative SACTs, different types of malignancy presented with large variations for the improved indicator, ranging from above 10% for gastroesophageal, pancreatic and lung cancers to below 4% for prostate cancers. The value of the improved indicator was significantly lower in the last years of the study period compared with the 2009-2011 period. The type of malignancy was also associated with significant differences. We defined an indicator adapted to the clinical context evaluating 30-day mortality following SACT. This indicator can be used to identify risk factors to help with clinical decision-making. A significant downward trend was observed in the 30-day mortality following palliative SACT over an 11-year period.

18 August 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
HSHella Sand
Hella Sand
JEJens Edmund
Jens Edmund
AAAne Appelt
Ane Appelt
PWPatrick Wohlfahrt
Patrick Wohlfahrt
VTVicki Trier Taasti
Vicki Trier Taasti
MNMartin Skovmos Nielsen
Martin Skovmos Nielsen
Background and purpose: Dual-energy computed tomography (DECT) is increasingly used in radiotherapy delineation due to its enhanced soft tissue contrast. DECT also supports direct dose calculation. However, as most current DECT scanners allow for use in only certain body regions, conventional single-energy computed tomography (SECT) is still needed for some patients. A safe clinical introduction of DECT thus requires a combined workflow. This study therefore investigates whether a unified Hounsfield look-up table (HLUT) can be applied across SECT and DECT reconstructions. Patient/material and methods: A Gammex Advanced Electron Density phantom containing tissue-equivalent inserts was scanned using SECT (70–140 kVp and Sn100–Sn140 kVp, Sn meaning tin-filtered) and dual-spiral DECT to identify matching HLUTs for three SECT methods, including a standard reconstruction (only 120 kVp; Method 1), and kVp-independent reconstructions providing mass density (MD; Method 2) or relative electron density (RED; Method 3). Dose agreement was subsequently tested on two anthropomorphic phantoms. For each SECT method, DECT reconstructions were compared through voxel-wise analysis of computed tomography (CT) numbers, and by performing dose calculations in three anatomical regions: head, thorax, and abdomen/pelvis. Results: Across all three SECT methods, DECT reconstructions with acceptable clinical CT number agreement were identified. Corresponding dose calculations between SECT- and DECT-based plans showed minimal differences. Interpretation: This phantom study demonstrates that a unified HLUT can be applied across SECT and DECT using standard 120 kVp, MD, or RED reconstructions. This approach may streamline clinical workflows and support a safe and practical transition to DECT-based treatment planning.

26 August 2022 in The European Journal of Health Economics
Verified
Journal Article
Closed access
PDF file
LBLars Børty
Lars Børty
RBRasmus Froberg Brøndum
Rasmus Froberg Brøndum
Heidi ChristensenHeidi Christensen
Heidi Christensen
CVCharles Vesteghem
Charles Vesteghem
MSMarianne Tang Severinsen
Marianne Tang Severinsen
MBMartin Bøgsted
Martin Bøgsted

6 January 2023 in BJS Open
Verified
Journal Article
Open access
PDF file
AEAlaa El-Hussuna
Alaa El-Hussuna
MKMaria Knudsen
Maria Knudsen
MFMatteo Frasson
Matteo Frasson
LPLaurids Østergaard Poulsen
Laurids Østergaard Poulsen
The aim of this study was to investigate the trends in morbidity and mortality of patients with right-sided colonic cancer who had an emergency surgical procedure in Denmark after the introduction of quality index parameters. This was a retrospective nationwide study based on a prospectively maintained Danish Colorectal Cancer Group database focused on right-sided colonic cancer in the interval from 1 May 2001 to 30 April 2018, who underwent emergency surgical intervention (within 48 h of hospital admission). The primary objective was to investigate the trends in morbidity and mortality throughout the study years. Multivariable estimates were adjusted for age, sex, smoking status, alcohol consumption, ASA score classification, tumour localization, type of access to abdominal cavity, surgeon’s grade of specialization, and metastatic disease. Out of 2839 patients, a total of 2740 patients fulfilled the inclusion criteria, of whom 2464 underwent right or transverse colon resection (89.9 per cent). The 30-day and 90-day postoperative mortality rates were significantly reduced over the time of the study (OR 0.943, 95 per cent c.i. 0.922 to 0.965, P < 0.001 and OR 0.953, 95 per cent c.i. 0.934 to 0.972, P < 0.001 respectively); however, the complication rates did not follow this trend. Older patients (OR 1.032, 95 per cent c.i. 1.009 to 1.055, P = 0.005) and patients with high ASA scores (OR 1.61, 95 per cent c.i. 1.422 to 1.830, P < 0.001) had higher rates of severe grade 3b postoperative complications. A stoma was constructed in 276 patients (10 per cent), whereas a stent was used in only eight patients. Defunctioning procedures, including stoma construction or colonic stenting (without oncological resection), did not reduce the risk of complications compared with that of definitive surgery. The 30-day and 90-day postoperative mortality rates were significantly reduced over the time of the study. Age and ASA score were risk factors for severe postoperative complications.